Skip to content
The biotech IPO outlook is strong, say experts
Biotech CEOs weathering a lean investment market got some good news from a panel of experts on Feb. 27. Following a couple of painfully […]
The biotech IPO outlook is strong, say experts Read More »
Lawmakers back bipartisan legislation supporting rare disease research
Bipartisan legislation to support research into rare diseases received backing from witnesses and lawmakers during a Feb. 29 hearing of the House Energy and
Lawmakers back bipartisan legislation supporting rare disease research Read More »
Biotech investment is scarce, but still available, experts tell CEOs
Even in this challenging market, biotechnology firms are attracting investment and building capital, but they need more than just a great innovation. They also
Biotech investment is scarce, but still available, experts tell CEOs Read More »
Drug developers and investors need to join AI revolution, panel says
Artificial intelligence and machine learning have boosted drug development and enhanced the value of biotech firms for years, but investors and companies need to
Drug developers and investors need to join AI revolution, panel says Read More »
CEOs say market must keep up with the science of gene therapies
The science of gene therapies is progressing at a remarkable pace, but if these medicines are going to reach patients, trends in investment and
CEOs say market must keep up with the science of gene therapies Read More »
BIO Board member tells Congress WTO IP waivers hurt innovation
A proposed World Trade Organization (WTO) IP waiver could have scuttled investment in biotech’s new diabetes drug and already impacts the firm’s decisions about
BIO Board member tells Congress WTO IP waivers hurt innovation Read More »
Congressional action BIO wants to see in 2024
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year. BIO’s
Congressional action BIO wants to see in 2024 Read More »
Loss of tax incentive for R&D threatens biotech innovation
After two decades of research and development, Sutro Biopharma is still a few years away from seeking market approval for its first drug, a
Loss of tax incentive for R&D threatens biotech innovation Read More »
FTC’s aggressive questions on patents registered with FDA is harmful overreach, expert says
The Federal Trade Commission (FTC) challenge of more than 100 patent listings registered with the Food and Drug Administration, mostly for devices used to
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel
The proposed updated European Union General Pharmaceutical Legislation offers some opportunities but also creates some new threats for biotech—and when it becomes law in
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel Read More »